Other languages Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Real-time Estimate Tradegate Other stock markets 03:20:05 2024-07-16 pm EDT			5-day change	1st Jan Change
2.354 ^EUR	+5.00%		+0.04%	+8.56%

Jun. 26	Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	MT
Jun. 26	Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	Jun. 26
Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	Jun. 26
Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.	Jun. 25
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket	Jun. 12
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024	Jun. 10
Compugen Names David Silberman CFO	May. 15
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Treasurer and Secretary, Effective July 12, 2024	May. 13
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	Mar. 19
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors	Jan. 19
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024	Dec. 19
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	23-08-02
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	23-08-02
Oramed Pharmaceuticals Says Hefei Tianhui Biotechnology Completes Phase 3 Trial of Oral Insulin; Shares Rise	23-05-15
Oramed Pharmaceuticals Inc. Announces its Chinese Partner, Hefei Tianhui Biotechnology Co. Ltd. Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Other languages

Filters